Radioimmunotherapy for B-cell non-Hodgkin lymphoma - PubMed (original) (raw)
Affiliations
- PMID: 16728934
Review
Radioimmunotherapy for B-cell non-Hodgkin lymphoma
Grzegorz S Nowakowski et al. Clin Adv Hematol Oncol. 2006 Mar.
Abstract
Radioimmunotherapy is an established and effective treatment in B-cell non-Hodgkin lymphoma (NHL). Currently, two radioimmunoconjugates (RICs) are approved for clinical use in the United States, ibritumomab tiuxetan and tositumomab. Both agents target the CD20 antigen on B-cell lymphoma cells. Although there are differences between these two agents, such as different murine monoclonal antibodies, radioisotopes, and dosimetry techniques, they share similar toxicity and efficacy profiles. These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope. This review focuses on the current use of these agents in the treatment of previously untreated indolent NHL and relapsed/refractory and transformed NHL.
Similar articles
- Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE. Witzig TE. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5. doi: 10.1007/s002800100312. Cancer Chemother Pharmacol. 2001. PMID: 11587375 Review. - Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE. Witzig TE. Best Pract Res Clin Haematol. 2006;19(4):655-68. doi: 10.1016/j.beha.2006.05.002. Best Pract Res Clin Haematol. 2006. PMID: 16997175 Review. - Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
Tobinai K. Tobinai K. Int J Clin Oncol. 2003 Aug;8(4):212-23. doi: 10.1007/s10147-003-0295-y. Int J Clin Oncol. 2003. PMID: 12955576 Review. - Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Meredith RF, Knox SJ. Meredith RF, et al. Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S15-22. doi: 10.1016/j.ijrobp.2006.04.059. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979433 Review.
Cited by
- EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
Lee JW, Stone RL, Lee SJ, Nam EJ, Roh JW, Nick AM, Han HD, Shahzad MM, Kim HS, Mangala LS, Jennings NB, Mao S, Gooya J, Jackson D, Coleman RL, Sood AK. Lee JW, et al. Clin Cancer Res. 2010 May 1;16(9):2562-70. doi: 10.1158/1078-0432.CCR-10-0017. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388851 Free PMC article. - Theranostic applications of antibodies in oncology.
Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC. Fleuren ED, et al. Mol Oncol. 2014 Jun;8(4):799-812. doi: 10.1016/j.molonc.2014.03.010. Epub 2014 Mar 21. Mol Oncol. 2014. PMID: 24725480 Free PMC article. Review. - Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma.
Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Brown RD, Kraemer DF, Soussain C, Neuwelt EA. Jahnke K, et al. Neuro Oncol. 2009 Oct;11(5):503-13. doi: 10.1215/15228517-2008-119. Epub 2009 Jan 21. Neuro Oncol. 2009. PMID: 19158414 Free PMC article. - Diagnosis and management of primary intraocular lymphoma: an update.
Jahnke K, Thiel E, Abrey LE, Neuwelt EA, Korfel A. Jahnke K, et al. Clin Ophthalmol. 2007 Sep;1(3):247-58. Clin Ophthalmol. 2007. PMID: 19668478 Free PMC article. - EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW, Han HD, Shahzad MM, Kim SW, Mangala LS, Nick AM, Lu C, Langley RR, Schmandt R, Kim HS, Mao S, Gooya J, Fazenbaker C, Jackson D, Tice DA, Landen CN, Coleman RL, Sood AK. Lee JW, et al. J Natl Cancer Inst. 2009 Sep 2;101(17):1193-205. doi: 10.1093/jnci/djp231. Epub 2009 Jul 29. J Natl Cancer Inst. 2009. PMID: 19641174 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous